# ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/ADMA/adma-biologics-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: ADMA
Company: ADMA Biologics
Source: ADMA Biologics
Published: 2026-05-06 20:05 EST
Original Source URL: https://ir.admabiologics.com
## Summary

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA ( 2) of $59.7 Million, Representing 24% Year-Over-Year

## Article Body
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA ( 2) of $59.7 Million, Representing 24% Year-Over-Year
## Recent Company News
- 2026-05-06 20:05 EST — [ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ADMA/adma-biologics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: ADMA Biologics
- 2026-05-04 11:00 EST — [ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older](https://biopharmsignal.com/news/ADMA/adma-biologics-announces-fda-approval-to-expand-the-label-for-ascenivtm-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older) — Source: ADMA Biologics
- 2026-04-29 11:00 EST — [ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/ADMA/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: ADMA Biologics
- 2026-03-27 11:00 EST — [ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research](https://biopharmsignal.com/news/ADMA/adma-biologics-issues-statement-refuting-unsubstantiated-misleading-and-inaccurate-allegations-by-culper-research) — Source: ADMA Biologics
- 2026-03-25 10:30 EST — [ADMA Biologics Addresses Misleading Short-Seller Report](https://biopharmsignal.com/news/ADMA/adma-biologics-addresses-misleading-short-seller-report) — Source: ADMA Biologics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)